Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
Anticancer Res. 2020 Jan;40(1):427-433. doi: 10.21873/anticanres.13970.
BACKGROUND/AIM: The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS).
We retrospectively identified NSCLC patients harboring KRAS mutation treated with IO in our Institution. We analyzed the results in comparison to non-KRAS patients.
Among 328 consecutive KRAS NSCLC patients, 43 (13.1%) received IO in our Institution. In parallel 117 non-KRAS NSCLC patients treated with IO were selected for comparison. The baseline characteristics were similar between the two groups. No significant difference was observed between KRAS and non-KRAS patients in terms of mPFS (4.6 vs. 3.3 months, p=0.58) or OS (8.1 vs. 13.0 months, p=0.38).
KRAS mutations seem to be irrelevant for selecting patients for IO that could be therefore considered an effective therapy for NSCLC patients, independently of KRAS status.
背景/目的：抗 PD1/PD-L1 治疗（IO）在携带驱动突变的非小细胞肺癌（NSCLC）中的作用仍存在争议。本研究旨在探讨 IO 在携带 KRAS 突变（KRAS）的非小细胞肺癌（NSCLC）患者中的疗效。
我们回顾性地确定了在我院接受 IO 治疗的携带 KRAS 突变的 NSCLC 患者。我们将结果与非 KRAS 患者进行了比较。
在 328 例连续的 KRAS NSCLC 患者中，有 43 例（13.1%）在我院接受 IO 治疗。同时，选择了 117 例接受 IO 治疗的非 KRAS NSCLC 患者作为对照。两组患者的基线特征相似。KRAS 组和非 KRAS 组患者在 mPFS（4.6 个月 vs. 3.3 个月，p=0.58）或 OS（8.1 个月 vs. 13.0 个月，p=0.38）方面无显著差异。
KRAS 突变似乎与选择接受 IO 治疗的患者无关，因此 IO 可能是一种有效的 NSCLC 患者治疗方法，与 KRAS 状态无关。
